Chemokines and their receptors: Orchestrating a fine balance between health and disease

Critical Reviews in Biotechnology

Volumn 30, Issue 1, 2010, Pages 1-22

  Sharma, Monika ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Agonists and antagonists; Chemoattraction; Chemokine receptors and signaling; Drug targets; Inflammation; Leukocyte trafficking

Indexed keywords

ANGIOGENESIS; BENEFICIAL EFFECTS; CELLULAR COMMUNICATION; CENTRAL NERVOUS SYSTEMS; CHEMOATTRACTION; CHEMOKINE RECEPTORS; CHEMOKINES; CYTOKINES; DRUG TARGETS; INFECTIOUS DISEASE; INFLAMMATORY RESPONSE; PATHOPHYSIOLOGY; RECEPTOR PROTEINS; TISSUE REPAIR; TRANS-MEMBRANE DOMAINS; TUMOR PROGRESSIONS;

ACTIVATION ANALYSIS; PATHOLOGY; SIGNALING; TARGETS;

PEPTIDES;

CHEMOKINE; CHEMOKINE RECEPTOR;

ALLERGY; ANGIOGENESIS; ASTHMA; AUTOIMMUNE DISEASE; BRAIN FUNCTION; CANCER GROWTH; CROHN DISEASE; CYTOKINE PRODUCTION; FETUS DEVELOPMENT; GENE EXPRESSION REGULATION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOCHEMISTRY; IMMUNOMODULATION; IMMUNOREGULATION; INFECTION; INFLAMMATION; KIDNEY DISEASE; LEUKOCYTE MIGRATION; LIVER DISEASE; LYMPHOCYTE DIFFERENTIATION; METASTASIS; NONHUMAN; ORGAN TRANSPLANTATION; ORGANOGENESIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; ULCERATIVE COLITIS;

ANIMALS; CHEMOKINES; DISEASE; HEALTH; HUMANS; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION;

EID: 76749152880     PISSN: 07388551     EISSN: 15497801     Source Type: Journal    
DOI: 10.3109/07388550903187418     Document Type: Review

References (230)

1. Abbas AK, Murphy KM, Sher A. 1996. Functional diversity of helper T lymphocytes. Nature 383:787-793.
2. Abdi R, Smith RN, Makhlouf L, Najafan N, Luster AD, Auchincloss H Jr, Sayegh MH. 2002. Te role of CC chemokine receptor 5 (CCR5) in islet allograft rejection. Diabetes 51:2489-2495.
3. Abdi R, Means TK, Ito T, Smith RN, Najafan N, Jurewicz M, Tchipachvili V, Charo I, Auchincloss H Jr, Sayegh MH, Luster AD. 2004. Diferential role of CCR2 in islet and heart allograft rejection: tissue specifcity of chemokine/ chemokine receptor function in vivo. J Immunol 172:767-775.
4. Aford SC, Fisher NC, Neil DA, Fear J, Brun P, Hubscher SG, Adams DH. 1998. Distinct patterns of chemokine expression are associated with leucocyte recruitment in alcoholic hepatitis and alcoholic cirrhosis. J Pathol 186:82-89.
5. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC. 1997. Te chemokine SDF-1 is a chemoattractant for human CD34̀ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34̀ progenitors to peripheral blood. J Exp Med 185:11-20.
6. Ajuebor MN, Flower RJ, Hannon R, Christie M, Bowers K, Verity A, Perretti M. 1998. Endogenous monocyte chemoattractant protein-1 recruits monocytes in the zymosan peritonitis model. J Leukoc Biol 63: 108-116.
7. Ajuebor MN, Das AM, Virag L, Flower RJ, Szabo C, Perretti M. 1999. Role of resident peritoneal macrophages and mast cells in chemokine production and neutrophil migration in acute infammation: evidence for an inhibitory loop involving endogenous IL-10. J Immunol 162:1685-1691.
8. Akashi S, Sho M, Kashizuka H, Hamada K, Ikeda N. 2005. A novel small molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection. Transplantation 80:378-384.
9. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA. 1996. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955-1958.
10. Ancuta P, Rao R, Moses A, Mehle A, Shaw SK, Luscinskas FW, Gabuzda D. 2003. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 197:1701-1707.
11. Ansari W, Hans H, Maren M, Reinhold S. 2007. Dichotomous efects of C-C chemokines in HIV-1 pathogenesis. Immunol Lett 110:1-5.
12. Arvanitakis L, Geras E, Varma A, Gershengorn MC, Cesarman E. 1997. Human herpesvirus KSHV encodes a constitutively active G protein coupled receptor linked to cell proliferation. Nature 385:347-350.
13. Bacon KB, Szabo MC, Yssel H, Bolen JB, Schall TJ. 1996. RANTES induces tyrosine kinase activity of stably complexed p125FAK and ZAP-70 in human T cells. J Exp Med 184:873.
14. Baggiolini M. 1998. Chemokines and leukocyte trafc. Nature 392:565-568.
15. Baggiolini M, Clark-Lewis I. 1992. Interleukin-8, a chemotactic and infammatory cytokine. FEBS Lett 307:97-101.
16. Baggiolini M, Dewbald B, Moser B. 1994. Interleukin-8 and related chemostatic cytokines: CXC and CC chemokines. Adv Immunol 55:97-197.
17. Baggiolini M, Dewald B, Moser B. 1997. Human chemokines: an update. Annu Rev Immunol 15:675-705.
18. Baker MS, Chen X, Rotramel AR, Nelson JJ, Lu B, Gerard C, Kanwar Y, Kaufman DB. 2003. Genetic deletion of chemokine receptor CXCR3 or antibody blockade of its ligand IP-10 modulates posttransplantation graft-site lymphocytic infltrates and prolongs functional graft survival in pancreatic islet allograft recipients. Surgery 134:126-133.
19. Barber DF, Bartolome A, Hernandez C, Flores JM, Redondo C, Fernandez-Arias C, Camps M, Rückle T, Schwarz MK, Rodríguez S, Martinez-A C, Balomenos D, Rommel C, Carrera AC. 2005. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 11:933-935.
20. Barnes PJ. 1997. Nuclear factor kappa B. Int J Biochem Cell Biol 29:867-870.
21. Barnwell JW, Nichols ME, Rubinstein P. 1989. In vitro evaluation of the role of the Dufy blood group in erythrocyte invasion by Plasmodium vivax. J Exp Med 169:1795.
22. Belperio JA, Keane MP, Burdick MD, Lynch JP III, Xue YY, Li K, Ross DJ, Strieter RM. 2002. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol 169:1037-1049.
23. Bertini R, Allegretti M, Bizzarri C, Moriconi A, Locati M, Zampella G, Cervellera MN, Di Cioccio V, Cesta MC, Galliera E, Martinez FO, Di Bitondo R, Troiani G, Sabbatini V, D'Anniballe G, Anacardio R, Cutrin JC, Cavalieri B, Mainiero F, Strippoli R, Villa P, Di Girolamo M, Martin F, Gentile M, Santoni A, Corda D, Poli G, Mantovani A, Ghezzi P, Colotta F. 2004. Noncompetitive allosteric inhibitors of the infammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci USA 101: 11791-11796.
24. Bettelli E, Oukka M, Kuchroo VK. 2007. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 8:345-350.
25. Biscof SC, Brunner T, De Weck AL, Dahinden CA. 1990. Interleukin-5 modifes histamine release and leukotriene generation by human basophils in response to diverse agonists. J Exp Med 172:1577-1582.
26. Bizzarri C, Beccari AR, Bertini R, Cavicchia MR, Giorgini S, Allegretti M. 2006. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Ter 112:139-149.
27. Bleul CC, Schultze JL, Springer TA. 1998. B lymphocyte chemotaxis regulated in association with microanatomic localization, diferentiation state, and B cell receptor engagement. J Exp Med 187:53-62.
28. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. 1998. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-defcient mice. J Clin Invest 101:353-363.
29. Bokoch GM. 1995. Chemoatractant signaling and leukocyte activation. Blood 86:1649-1660.
30. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F. 1998. Diferential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (T1s) and T2s. J Exp Med 187:129-134.
31. Boring L, Gosling J, Chensue SW, Kunkel SL, Farese RV Jr, Broxmeyer HE, Charo IF. 1997. Impaired monocyte migration and reduced type 1 (T1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 100: 2552-2561.
32. Boring L, Gosling J, Cleary M, Charo IF. 1998. Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394:894-897.
33. Brady HR. 1994. Leukocyte adhesion molecules and kidney disease. Kidney Int 4:1285-1300.
34. Brightling CE, Kaur D, Berger P, Morgan AJ, Wardlaw AJ, Bradding P. 2005. Diferential expression of CCR3 and CXCR3 by human lung and bone marrow-derived mast cells: implications for tissue mast cell migration. J Leukoc Biol 77:759-766.
35. Burger J, Kipps T. 2006. XCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107:1761-1767.
36. Butcher EC, Picker LJ. 1996. Lymphocyte homing and homeostasis. Science 272:60-76.
37. Cadene M, Boudier C, de Marcillac GD, Bieth JG. 1995. Infuence of low molecular mass heparin on the kinetics of neutrophil elastase inhibition by mucus proteinase inhibitor. J Biol Chem 270:13204-13209.
38. Campanella GSV, Grimm J, Manice LA, Colvin RA, Medof BD, Wojtkiewicz GR, Weissleder R, Luster AD. 2006. Oligomerization of IP-10 is necessary for endothelial cell presentation and in vivo activity. J Immunol 177:6991-6998.
39. Campbell JJ, Butcher EC. 2000. Chemokine in tissue specifc and microenvironment-specifc lymphocyte homing. Curr Opin Immunol 12:336-341.
40. Campbell JJ, Foxman EF, Butcher EC. 1997. Chemoattractant receptor cross talk as a regulatory mechanism in leukocyte adhesion and migration. Eur J Immunol 27:2571-2578.
41. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Françon B, Martin T, Gretener D, Perrin D, Leroy D, Vitte PA, Hirsch E, Wymann MP, Cirillo R, Schwarz MK, Rommel C. 2005. Blockade of PI3Kgamma suppresses joint infammation and damage in mouse models of rheumatoid arthritis. Nat Med 11:936-943.
42. Cassatella MS. 1995. Te production of cytokines by polymorphonuclear neutrophils. Immunol Today 16:21-26.
43. Chang M, McNinch J, Elias C, Manthey C, Grosshans D, Meng T, Boone T, Andrew D. 1997. Molecular cloning and functional characterization of a novel CC chemokine, stimulated T cell chemotactic protein (STCP-1) that specifcally acts on activated T lymphocytes. J Biol Chem 272:25229-25237.
44. Chapman GA, Moores KE, Gohil J, Berkhout TA, Patel L, Green P, Macphee CH, Stewart BR. 2000. Te role of fractalkine in the recruitment of monocytes to the endothelium. Eur J Pharmacol 392:189-195.
45. Chute JP. 2006. Stem cell homing. Curr Opin Hematol 13:399-406.
46. Cobbold S, Waldmann H. 1998. Infectious tolerance. Curr Opin Immunol 10:518-524.
47. Collins PD, Marleau S, Grifths DA, Jose PJ, Williams TJ. 1995. Cooperation between interleukin-5 and chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 182:1169-1174.
48. Cook DN, Beck MA, Cofman TM, Kirby SL, Sheridan JF, Pragnell IB, Smithies O. 1995. Requirement of MIP-1 alpha for an infammatory response to viral infection. Science 269:1583-1585.
49. Craig M, Adam F. 2000. Chemokine receptors and the role in infammation and infectious disease. J Am Society Hematol 95:3032-3043.
50. Cupedo T, Mebius RE. 2003. Role of chemokines in the development of secondary and tertiary lymphoid tissues. Semin Immunol 15:243-248.
51. D'Apuzzo M, Rolink A, Loetscher M, Hoxie JA, Clark-Lewis I, Melchers F, Baggiolini M, Moser B. 1997. Te chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. Eur J Immunol 27:1788-1793.
52. D'Souza MP, Harden VA. 1996. Chemokines and HIV-1 second receptors: confuence of two felds generates optimism in AIDS research. Nat Med 2:1293-1300.
53. Das AM, Flower RJ, Perrett M. 1997. Eotaxin induced eosinophil migration in the peritoneal cavity of ovalbumin-sensitized mice: mechanism of action. J Immunol 159:1466-1473.
54. De Clercq E. 2003. Te bicyclam AMD3100 story. Nat Rev Drug Discov 2:581-587.
55. De Mendonca FL, da Fonseca PC, Phillips RM, Saldanha JW, Williams TJ, Williams TJ, Pease JE. 2005. Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist. J Biol Chem 280:4808-4816.
56. De Perrot M, Sekine Y, Fischer S, Waddell TK, McRae K, Liu M, Wigle DA, Keshavjee S. 2002. Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation. Am J Respir Crit Care Med 165:211-215.
57. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghof E, Gomperts E, Donfeld S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, O'Brien SJ. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene: Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273:1856-1862.
58. Del Prete A, Vermi W, Dander E, Otero K, Barberis L, Luini W, Bernasconi S, Sironi M, Santoro A, Garlanda C, Facchetti F, Wymann MP, Vecchi A, Hirsch E, Mantovani A, Sozzani S. 2004. Defective dendritic cell migration and activation of adaptive immunity in PI3Kgammadefcient mice. EMBO J 23:3505-3515.
59. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. 1996. Identifcation of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666.
60. DeVries ME, Hosiawa KA, Cameron CM, Bosinger SE, Persad D, Kelvin AA, Coombs JC, Wang H, Zhong R, Cameron MJ, Kelvin DJ. 2003. Te role of chemokines and chemokine receptors in alloantigen-independent and alloantigen-dependent transplantation injury. Semin Immunol 15:33-48.
61. Dommit R. 2008. Chemokines and cytokines: a primer of cellular biology of the clinical neonatalogist. Neo Rev 9:654.
62. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
63. Dragic T, Trkola A, Tompson DA, Cormier EG, Kajumo FA, Maxwell E, Lin SW, Ying W, Smith SO, Sakmar TP, Moore JP. 2000. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 97:5639-5644.
64. Eckmann L, Reed SL, Smith JR, Kagnof MF. 1995. Entamoeba histolytica trophozoites induce an infammatory cytokine response by cultured human cells through the paracrine action of cytolytically released interleukin-1a. J Clin Invest 96:1269-1271.
65. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Terada K, Geula C, Luster AD. 2007. CCR2 defciency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13:432-438.
66. Elliott SN, Wallace JL. 1998. Neutrophil-mediated gastrointestinal injury. Can J Gastroenterol 12:559-568.
67. Feng Y, Broder CC, Kennedy PE, Berger EA. 1996. HIV-1 entry cofactor: functional cDNA cloning of e seven transmembrane, G protein-coupled receptor. Science 272:872-877. (Pubitemid 26154590)
68. Finkelman FD, Shea-Donohue T, Morris SC, Gildea L, Strait R, Madden KB, Schopf L, Urban JF Jr. 2004. Interleukin-4-and interleukin-13-mediated host protection against intestinal nematode parasites. Immunol Rev 201:139-155.
69. Fischereder M, Luckow B, Hocher B, Wuthrich RP, Rothenpieler U, Schneeberger H, Panzer U, Stahl RA, Hauser IA, Budde K, Neumayer H, Krämer BK, Land W, Schlöndorf D. 2001. CC chemokine receptor 5 and renal-transplant survival. Lancet 357:1758-1761.
70. Fisher NC, Neil DA, Williams A, Adams DH. 1999. Serum concentrations and peripheral secretion of the beta chemokines monocyte chemotactic protein 1 and macrophage infammatory protein 1a in alcoholic liver disease. Gut 45:416-420.
71. Fujisawa N, Hayashi S, Kurdowska A, Carr FK, Miller EJ. 1999. Inhibition of GROalpha-induced human endothelial cell proliferation by the alpha-chemokine inhibitor antileukinate. Cytokine 11:231.
72. Furie MB, Randolph GJ. 1995. Chemokines and tissue injury. Am J Pathol 146:1287-1301.
73. Ganju RK, Dutt P, Wu L, Newman W, Avraham H, Avraham S, Groopman JE. 1998. Beta-chemokine receptor CCR5 signals via the novel tyrosine kinase RAFTK. Blood 91:791.
74. Geissmann F, Jung S, Littman DR. 2003. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19: 71-82.
75. Gelmini S, Mangoni M, Serio M, Ramagvani P, Lazzeri E. 2008. Te critical role of SDF-1/CXCR4 axis in cancer and cancer stem cell metastasis. J Endocronol Invest 31:809-819.
76. Ghazal B, Stephane P. 2005. Chemokines and brain function. Current drug targets. Infam Allergy 4:387-399.
77. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnálek P, Zádorová Z, Palmer T, Donoghue S; Natalizumab Pan-European Study Group. 2003. Natalizumab for active Crohn's disease. N Engl J Med 348:24-32.
78. Glass WG, Hickey MJ, Hardison JL, Liu MT, Manning JE, Lane TE. 2004. Antibody targeting of the CC chemokine ligand 5 results in diminished leukocyte infltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis. J Immunol 172:4018-4025.
79. Godiska R, Chantry D, Raport CJ, Sozzani S, Allavena P, Leviten D, Mantovani A, Gray PW. 1997. Human macrophage derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J Exp Med 185:1595-1604.
80. Gong JH, Clark-Lewis I. 1997. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MPL-lpr mouse model. J Exp Med 186:131-137.
81. Goodarzi K, Goodarzi M, Tager AM, Luster AD, von Andrian UH. 2003. Leukotriene B4 and BLT1 control cytotoxic efector T cell recruitment to infamed tissues. Nat Immunol 4:965-973.
82. Gracia-Zepeda EA, Combadiere C, Rothenberg ME, Saraf MN, Lavigne F, Hamid Q, Murphy PM, Luster AD. 1996. Human monocyte chemoattractant protein (MCP)-4 is a novelchemokine with activities on monocytes, eosinophils and basophils induced in allergic and nonallergic infammation that signals through the CC chemokine receptors (CCR)-2 and 3. J Immunol 157: 5613-5626.
83. Grandaliano G, Gesualdo L, Ranieri E, Monno R, Montinaro V Marra F, Schena FP. 1996. Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment. J Am Soc Nephrol 7:906-913.
84. Grewal IS, Rutledge BJ, Fiorillo JA, Gu L, Gladue RP, Flavell RA, Rollins BJ. 1997. Transgenic monocyte chemoattractant protein-1 (MCP-1) in pancreatic islets produces monocyte-rich insulitis without diabetes: abrogation by a second transgene expressing systemic MCP-1. J Immunol 159:401-408.
85. Gröne HJ, Weber C, Weber KSC, Gröne EF, Rabelink T, Klier CM, Wells TNC, Proudfoot AE, Schlondorf D, Nelson PJ. 1999. Met-RANTES-reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J 13:1371-1383.
86. Gupta SK, Singh JP. 1994. Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J Cell Biol 127:1121.
87. Hamada T, Mohle R, Hesselgesser J, Hoxie J, Nachman RL, Moore MA, Rafi S. 1998. Transendothelial migration of megakaryocytes in response to stromal cell-derived factor 1 (SDF-1) enhances platelet formation. J Exp Med 188:39-48.
88. Hancock WW, Lu B, Gao W, Csizmadia V Faia K, King JA, Smiley ST, Ling M, Gerard NP, Gerard C. 2000. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 192:1515-1520.
89. Hancock WW, Wang L, Ye Q, Han R, Lee I. 2003. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol 15:479-486.
90. Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K. 1994. Essential involvement of interleukin-8 (IL-8) in acute infammation. J Leukoc Biol 56:559-564.
91. Harris JG, Flower RJ, Watanbe K, Tsursufugi S, Wolitzky BA, Perretti M. 1996. Relative contribution of the selectins in the neutrophil recruitment caused by the chemokine cytokine-induced neutrophil chemoattractant (CINC). Biochem Biophys Res Commun 221:692-696.
92. Heck S, Bender K, Kullmann M, Gottlicher M, Herrlich P, Cato AC. 1997. IKB alpha-independent downregulation of NF-KB activity by glucocorticoid receptor. EMBO J 16:4698-4707.
93. Hedrick JA, Saylor V Figueroa D, Mizoue L, Xu Y, Menon S, Abrams J, Handel T, Zlotnik A. 1997. Lymphotactin is produced by NK cells and attracts both NK cells and T cells in vivo. J Immunol 158: 1533-1540.
94. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E, Bridger G, Henson GW. 2000. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 44:1667-1673.
95. Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, Silengo L, Sozzani S, Mantovani A, Altruda F, Wymann MP. 2000. Central role for G protein-coupled phosphoinositide 3-kinase gamma in infammation. Science 287:1049-1053.
96. Hjelmstrom P. 2001. Lymphoid neogenesis: de novo formation of lymphoid tissue in chronic infammation through expression of homing chemokines. J Leukoc Biol 69: 331-339.
97. Horuk R, Chitnis CE, Darbonne WC, Colby TJ, Rybicki A, Hadley TJ, Miller LH. 1993. A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science 262:1182-1184.
98. Horuk R. 1994. Molecular properties of the chemokine receptor family. Trends Pharmacol Sci 15:159-165.
99. Huang R, Lian JP, Robinson D, Badwey JA. 1998. Neutrophils stimulated with a variety of chemoattractants exhibit rapid activation of p21-activated kinases (Paks): separate signals are required for activation and inactivation of paks. Mol Cell Biol 18:7130.
100. Humbert M, Ying S, Conigan C, Menz G, Barkans J, Pfster R, Meng Q, Van Damme J, Opdenakker G, Durham SR, Kay AB. 1997. Bronchial mucosal expression of the genes encoding chemokine RANTES and MCP-3 in symptomatic atopic and nonatopic asthmatics: relationship to the eosinophil active cytokines interleukin-5, granulocyte macrophage colony stimulating factor, and IL-13. Am J Respir Cell Mol Biol 16: 1-8.
101. Imai T, Yoshida T, Baba M, Nishimura M, Kakizaki M, Yoshie O. 1996. Molecular cloning of a novel T cell-directed CC chemokine expressed in thymus by signal sequence trap using Epstein-Barr virus vector. J Biol Chem 271:21514-21521.
102. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, Yoshie O. 1997. Identifcation and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91: 521-530.
103. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD. 2000. Resistance to experimental autoimmune encephalomyelitis in mice lacking the Chemokine receptor (CCR)2. J Exp Med 192:1075-1080.
104. Jarmin DI, Kulmburg PA, Huber NE, Baumann G, Prieschl Strassmayr EE, Baumruker T. 1994. A transcription factor with AP3-like binding specifcity mediates gene regulation after an allergic triggering with IgE and Ag in mouse mast cells. J Immunol 153:5720-5729.
105. Johnson Z, Kosco-Vilbois MH, Herren S, Cirillo R, Muzio V, Zaratin P, Carbonatto M, Mack M, Smailbegovic A, Rose M, Lever R, Page C, Wells TN, Proudfoot AE. 2004. Interference with heparin binding and oligomerization creates a novel anti-infammatory strategy targeting the chemokine system. J Immunol 173:5776-5785.
106. Johnson Z, Proudfoot AE, Handel TM. 2005. Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev 16:625-636.
107. Kakinuma T, Hwang ST. 2006. Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 79:639-651.
108. Kampten GT, Staford S, Poulsen LK, Alam R. 1998. Te MAP kinase ERK2 is activated through CC chemokine receptor 3 (CCR3) and is essential for eotaxin-stimulated eosinophil chemotaxis. J Allergy Exp Immunol 101:223.
109. Kaneider NC, Agarwal A, Leger AJ, Kuliopulos A. 2005. Reversing systemic infammatory response syndrome with chemokine receptor pepducins. Nat Med 11:661-665.
110. Karlmark KR, Wasmuth HE, Trautwein C, Tacke F. 2008. Chemokine-directed immune cell infltration in acute and chronic liver disease. Expert Rev Gastroenterol Hepatol 2:233-242.
111. Kim CH, Pelus LM, White JR, Broxmeyer HE. 1998. Diferential chemotactic behavior of developing T cells in response to thymic chemokines. Blood 91:434-443.
112. Kim CH, Rott L, Kunkel EJ, Genovese MC, Andrew DP, Wu L, Butcher EC. 2001. Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest 108:1331-1339.
113. Koch AE, Polverinim PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM. 1992. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258:1798.
114. Kunkel EJ, Campbell JJ, Haraldsen G, Pan J, Boisvert J, Roberts AI, Ebert EC, Vierra MA, Goodman SB, Genovese MC, Wardlaw AJ, Greenberg HB, Parker CM, Butcher EC, Andrew DP, Agace WW. 2000. Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: epithelial expression of tissue-specifc chemokines as an organizing principle in regional immunity. J Exp Med 192:761-768.
115. Laing K, Secombes C. 2004. Chemokines. Dev Comp Immunol 28:443-460.
116. Lamkhioued B, Renzi PM, Abi-Younes S, Garcia-Zepada EA, Allakhverdi Z, Ghafar O, Rothenberg MD, Luster AD, Hamid Q. 1997. Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of infammation. J Immunol 159:4593-4601.
117. Lapham CK, Ouyang J, Chandrasekhar B, Nguyen NY, Dimitrov DS, Golding H. 1996. Evidence of cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science 274:602-605.
118. Laudanna C, Campbell JJ, Butcher EC. 1996. Role of Rho in chemoattractant activated leukocyte adhesion through integrins. Science 271: 981-983.
119. Laurent F, Eckmann L, Savidge TC, Morgan G, Teodos C, Naciri M, Kagnof MF. 1997. Cryptosporidium parvum infection of human intestinal epithelial cells induces the polarized secretion of C-X-C chemokines. Infect Immun 65:5067-5073.
120. Lederman MM, Veazey RS, Oford R, Mosier DE, Dufour J, Meford M, Piatak M Jr, Lifson JD, Salkowitz JR, Rodriguez B, Blauvelt A, Hartley O. 2004. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306:485-487.
121. Legler DF, Loetscher M, Roos RS, Clark Lewis I, Baggiolini M, Moser B. 1998. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 187:655-660.
122. Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV, Wu D. 2000. Roles of PLC-beta2 and-beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science 287:1046-1049.
123. Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P, Farber JM. 1995. Human Mig chemokine: biochemical and functional characterization. J Exp Med 182:1301-1314.
124. Liu R, Paxton WA, Choe S, Ceradini C, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-377.
125. Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C, Rollins BJ. 1998. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-defcient mice. J Exp Med 187:601-608.
126. Lukaes NW, Streiter RM, Warmington K, Lincoln P, Cheustte SW, Kunkel SL. 1997. Diferential recruitment of leukocyte population and alteration of airway hyperreactivity by C-C family chemokines in allergic airway infammation. J Immunol 158:4398-4404.
127. Luster AD. 1998. Chemokines-chemotactic cytokines that mediate infammation. N Engl J Med 338:436-445.
128. Luster AD, Leder P. 1993. IP-10, a-C-X-C-chemokine, elicits a potent thymus dependent antitumor response in vivo. J Exp Med 178:1057-1065.
129. Luster AD, Rothenberg ME. 1997. Role of the monocyte chemotactic protein and eotaxin subfamily of chemokines in allergic infammation. J Leukoc Biol 62:620-633.
130. Ma Q, Jones D, Springer TA. 1999. Te chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 10:463-471.
131. Mahler DA, Huang S, Tabrizi M, Bell GM. 2004. Efcacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 126:926-934.
132. Mangan DF, Mergenhagen SE, Wahl SM. 1993. Apoptosis in human monocytes: possible role in chronic infammatory diseases. J Periodontol 64:461-466.
133. Mantovani A. 1999. Te chemokine system: redundancy for robust outputs. Immunol Today 20:254-257.
134. Mantovani A, Bonecchi R, Locati M. 2006. Tuning infammation and immunity by chemokine sequestration: decoys and more. Nat Rev Immunol 6:907-918.
135. Marra F, Romanelli RG, Giannini C, Failli P, Pastacaldi S, Arrighi MC, Pinzani M, Laf G, Montalto P, Gentilini P. 1999. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology 29:140-148.
136. Mellado M, Rodriguez-Frade JM, Aragay A, del Real G, Martín AM, Vila-Coro AJ, Serrano A, Mayor F Jr, Martínez-AC. 1998. Te chemokine monocyte chemotactic protein 1 triggers Janus kinase 2 activation and tyrosine phosphorylation of the CCR2B receptor. J Immunol 161:805.
137. Mezzano S, Droguett M, Burgos M, Ardiles L, Caorsi I, Egido J. 1998. In situ detection of chemokines (MCP-1, RANTES, IL-8), osteopontin, fbrogenic cytokines (PDGF, TGF-beta) and apoptotic cells in human idiopathic membranous nephropathy. J Am Soc Nephrol 9:463A.
138. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW; International Natalizumab Multiple Sclerosis Trial Group. 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15-23.
139. Miller LH, Mason SJ, Dvorak JA, McGinniss MH, Rothman IK. 1975. Erythrocyte receptors for (Plasmodium knowlesi) malaria: dufy blood group determinants. Science. 189:561.
140. Minshall EM, Cameron L, Lavigne F, Leung DY, Hamilos D, Garcia-Zepada EA, Rothenberg M, Luster AD, Hamid Q. 1997. Eotaxin mRNA and protein expression in chronic sinusitis and allergen induced nasal response I seasonal allergic rhinitis. Am J Respir Cell Mol Biol 17:683-690.
141. Moench C, Uhrig A, Lohse AW, Otto G. 2004. CC chemokine receptor 5delta32 polymorphism-a risk factor for ischemic-type biliary lesions following orthotopic liver transplantation. Liver Transpl 10:434-439.
142. Moore BB, Keane MP, Addison CL, Arenberg DA, Strieter RM. 1998. CXC chemokine modulation of angiogenesis: the importance of balance between angiogenic and angiostatic members of the family. J Invest Med 46:113-120.
143. Murdoch C, Monk PN, Finn A. 1999. CXC chemokine receptor expression on human endothelial cells. Cytokine 11:704.
144. Murphy PM. 1994. Te molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol 12: 593-633.
145. Murphy PM. 1996. Chemokine receptors: structure, function and role in microbial pathogenesis. Cytokine Growth Factor Rev 7:47-64.
146. Murphy PM. 1997. Neutrophil receptors for interleukin-8 and related CXC chemokines. Semin Hematol 34:311-318.
147. Murphy PM, Baggiolini M, Charo IF, Hébert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA. 2000. International union of pharmacology XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52:1452-1476.
148. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H, Kishimoto T. 1996. Defects of B-cell lymphopoiesis and bone marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382:636-638.
149. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. 1991. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 88:1121-1127.
150. Nelson PJ, Krensky AM. 1998. Chemokines, lymphocytes and viruses: what goes around, comes around. Curr Opin Immunol 10:265-270.
151. Nelson PJ, Krensky AM. 2001. Chemokines, chemokine receptors, and allograft ejection. Immunity 14:377-386.
152. Nelson PJ, Ortiz BD, Pattison JM, Krensky AM. 1996. Identifcation of a novel regulatory region critical for expression of the RANTES chemokine in activated T lymphocytes. J Immunol 157:1139-1148.
153. Panes J, Granger DN. 1998. Leukocyte endothelial cell interaction, molecular mechanisms and implications in gastrointestinal diseases. Gastroenterol 114:1066-1090.
154. Panzer U, Steinmetz OM, Paust HJ, Meyer-Schwesinger C, Peters A, Turner JE, Zahner G, Heymann F, Kurts C, Hopfer H, Helmchen U, Haag F, Schneider A, Stahl RA. 2007. Chemokine receptor CXCR3 mediates T cell recruitment and tissue injury in nephrotoxic nephritis in mice. J Am Soc Neph 18:2071-2084.
155. Paxton WA, Martin SR, Tse D, O'Brien TR, Skurnick J, VanDevanter NL, Padian N, Braun JF, Kotler DP, Wolinsky SM, Koup RA. 1996. Relative resistance to HIV-1 of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med 2:412-417.
156. Peveri P, Walz A, Dewald B, Baggiolini M. 1988. A novel neutrophil-activating factor produced by human mononuclear phagocytes. J Exp Med 167:1547-1559.
157. Proudfoot AE, Power CA, Hoogewerf AJ, Montjovent MO, Borlat F, Oford RE, Wells TN. 1996. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 271:2599-2603.
158. Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, Borlat F, Wells TN, Kosco-Vilbois MH. 2003. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 100:1885-1890.
159. Quackenbush EJ, Aguirre V, Wershil BK, Gutierrez Ramos JC. 1997. Eotaxin infuences the development of embryonic hematopoietic progenitors in the mouse. J Leukocyte Biol 62:661-666.
160. Reiss Y, Proudfoot AE, Power CA, Campbell JJ, Butcher EC. 2001. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafcking to infamed skin. J Exp Med 194:1541-1547.
161. Reynaud-Gaubert M, Marin V, Tirion X, Farnarier C, Tomas P, Badier M, Bongrand P, Giudicelli R, Fuentes P. 2002. Upregulation of chemokines in bronchoalveolar lavage fuid as a predictive marker of post-transplant airway obliteration. J Heart Lung Transplant 21:721-730.
162. Rollins BJ. 1997. Chemokines. Blood 90:909-938.
163. Romagnani P, Beltrame C, Annunziato F, Lasagni L, Luconi M, Galli G, Cosmi L, Maggi E, Salvadori M, Pupilli C, Serio M. 1999. Role for interactions between IP-10/MIG and CXCR3 in proliferative glomerulonephritis. J Am Soc Nephrol 10:2518-2526.
164. Ross R. 1995. Cell biology of atherosclerosis. Ann Rev Physiol 57:791.
165. Rossi D, Zlotnik A. 2000. Te biology of chemokines and their receptors. Ann Rev Immunonol 18:217-242.
166. Rot A. 1992. Endothelial cell binding of NAP-1/IL-8: role in neutrophil emigration. Immunol Today 13: 291-294.
167. Rovin BH, Tan LC. 1994. Role of protein kinase pathways in IL-1 induced chemoattractant expression by human mesangial cells. Kidney Int. 46:1059-1068.
168. Rovin BH, Dickerson JA, Tan LC, Fassler J. 1997. Modulation of IL-1-induced chemokine expression in human mesangial cells through alterations in redox status. Cytokine 9:178-186.
169. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, Kieran MW, Luster AD, Segal RA. 2003. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 100: 13513-13518.
170. Sallusto F, Lanzavecchia A, Mackay CR. 1998. Chemokines and chemokine receptors in T-cell priming and T1/T2-mediated responses. Immunol Today 19:568-574.
171. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M. 1996. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 332:722-725.
172. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, Bolon B, Wakeham A, Itie A, Bouchard D, Kozieradzki I, Joza N, Mak TW, Ohashi PS, Suzuki A, Penninger JM. 2000. Function of PI3K gamma in thymocyte development, T cell activation, and neutrophil migration. Science 287:1040-1046.
173. Satriano JA, Hora K, Shan Z, Stanley ER, Mori T, Schlöndorf D. 1993. Regulation of monocyte chemoattractant protein-1 and macrophage colony-stimulating factor-1 by IFN-7, tumor necrosis factor-a, IgG aggregates, and cAMP in mouse mesangial cells. J Immunol 150:1971-1978.
174. Savkovic S, Koutsouris A, Hecht J. 1996. Attachment of a noninvasive pathogen, enteropathogenic Escherichia coli, to cultured intestinal epithelial monolayers induces transmigration to neutrophils. Infect Immun 64:4480-4487.
175. Schlondorf D, Nelson PJ, Luckow B, Banas B. 1997. Chemokines and renal disease. Kidney Int 51:610-621.
176. Schols D. 2006. HIV coreceptor inhibitors as novel class of anti-HIV drugs. Antiviral Res 71:216-226.
177. Segerer S, Nelson PJ. 2005. Chemokines in renal diseases. Scientifc World J 5:835-844.
178. Segerer S, Mack M, Regele H, Kerjaschki D, Schlöndorf D. 1999. Expression of the C-C chemokine receptor 5 in human kidney diseases. Kidney Int 56:52-64.
179. Sekido N, Mukaida N, Harada A, Nakanishi I, Watanabe Y, Matsushima K. 1999. Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature 365:654-657.
180. Shaio MF, Lin PR, Liu JY, Yang JY. 1995. Generation of interleukin-8 from human monocytes in response to Trichomonas vaginalis stimulation. Infect Immun 63:3864-3870.
181. Sharafeldin A, Eltayeb R, Pashenkov M, Bakhiet M. 2000. Chemokines are produced in the brain early during the course of experimental African trypanosomiasis. J Neuroimmunol 103:163-170.
182. Sharma M, Vohra H, Bhasin D. 2005. Enhanced proinfammatory chemokine/ cytokine response triggered by pathogenic Entamoeba histolytica:basis of invasive disease. Parasitol 131:783-796.
183. Sharma M, Bhasin D, Vohra H. 2008. Diferential induction of immunoregulatory circuits of phagocytic cells by Gal/Gal NAc lectin from pathogenic and non-pathogenic Entamoeba. J Clin Immunol 28:542-557.
184. Sharpe RJ, Byers HR, Scott CF, Bauer SI, Maione TE. 1990. Growth inhibition of human melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 82:848-853.
185. Simmons G, Clapham PR, Picard L, Oford RE, Rosenkilde MM. 1997. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science. 276:276-279.
186. Simpson KJ, Henderson NC, Bone-Larson CL, Lukacs NW, Hogaboam CM, Kunkel SL. 2003. Chemokines in the pathogenesis of liver disease: so many players with poorly defned roles. Clin Sci (Lond) 104:47-63.
187. Springer TA. 1994. Trafc signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76:301-314.
188. Staford S, Li H, Forsythe PA, Ryan M, Bravo R, Alam R. 1997. Monocyte chemotactic protein-3 (MCP-3)/fbroblast-induced cytokine (FIC) in eosinophilic infammation of the airways and the inhibitory efect of an anti MCP-3/FIC antibody. J Immunol 158:4953-4960.
189. Steinmetz OM, Stahl R, Panzer U. 2009. Chemokines and B cells in renal infammation and allograft rejection. Fron Biosci (scholar edition) 1:13-22.
190. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, 1995. Te functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270:27348.
191. Streiter RM, Strandiford TJ, Hufnagle GB, Colletti LM, Lukaes NW, Kunkel SL. 1996. "Te good, the bad, and the ugly": the role of chemokines in models of human disease. J Immunol 156:3583-3586.
192. Tager AM, Bromley SK, Medof BD, Islam SA, Bercury SD, Friedrich EB, Carafone AD, Gerszten RE, Luster AD. 2003. Leukotriene B4 receptor BLT1 mediates early efector T cell recruitment. Nat Immunol 4:982-990.
193. Tan J, Zhou G. 2005. Chemokine receptors and transplantation. Cell Mol Immunol 2:343-349.
194. Tanabe S, Lu Z, Luo Y, Quackenbush EJ, Berman MA, Collins-Racie LA, Mi S, Reilly C, Lo D, Jacobs KA, Dorf ME. 1997. Identifcation of a new mouse betachemokine, thymus-derived chemotactic agent 4, with activity on T lymphocytes and mesangial cells. J Immunol 159:5671-5679.
195. Taub DD, Anver M, Oppenheim JJ, Longo DL, Murphy WJ. 1996. IL-8 induced degradation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J Clin Invest 97:1931-1941.
196. Tomas SY, Banerji A, Medof BD, Lilly CM, Luster AD. 2007. Multiple chemokine receptors, including CCR6 and CXCR3, regulate antigen-induced homing of T cells to the human asthmatic airway. J Immunol 179:1901-1912.
197. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, Moore JP. 1996. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384:184-187.
198. Turner SJ, Domin J, Waterfeld MD, Ward SG, Westwick J. 1998. Te CC chemokine monocyte chemotactic peptide-1 activates both the class I p85/p110 phosphatidylinositol 3-kinase and the class II PI3K-C2alpha. J Biol Chem 273:25987.
199. Ulbrich H, Eriksson EE, Lindbom L. 2003. Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in infammatory disease. Trends Pharmacol Sci 24:640-647.
200. Veazey RS, Klasse PJ, Ketas TJ, Reeves JD, Piatak M Jr, Kunstman K, Kuhmann SE, Marx PA, Lifson JD, Dufour J, Meford M, Pandrea I, Wolinsky SM, Doms RW, DeMartino JA, Siciliano SJ, Lyons K, Springer MS, Moore JP 2003. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodefciency virus infection or prevent simian-human immunodefciency virus infection. J Exp Med 198:1551-1562.
201. Veazey RS, Springer MS, Marx PA, Dufour J, Klasse PJ, Moore JP. 2005. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med 11:1293-1294. (Pubitemid 41752908)
202. Verani A, Lusso P. 2002. Chemokines as Natural HIV Antagonists. Curr Mol Med 2:691-702.
203. Vielhauer V Anders HJ. 2009. Chemokines and chemokine receptors as therapeutic targets in chronic kidney disease. Fron Biosci 1:1-12.
204. Viola A, Luster A. 2008. Chemokines and their receptors: drug targets in immunity and infection. Ann Rev Pharmacol Toxicol 48:171-197.
205. Volin MV, Joseph L, Shockley MS, Davies PF. 1998. Chemokine receptor CXCR4 expression in endothelium. Biochem Biophys Res Commun 242:46.
206. Wada T, Tomosugi N, Naito T, Yokoyama H, Kobayashi K, Harada A, Mukaida N, Matsushima K. 1994. Prevention of proteinurea by the administration of anti interleukin-8 antibody in experimental acute immune complex-induced glomerulonephritis. J Exp Ed 180:1135-1140.
207. Wada T, Furuichi K, Segawa-Takaeda C, Shimizu M, Sakai N, Takeda SI, Takasawa K, Kida H, Kobayashi KI, Mukaida N, Ohmoto Y, Matsushima K, Yokoyama H. 1999. MIP-1a and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int 56:995-1003.
208. Wald O, Pappo O, Safadi R, Dagan-Berger M, Beider K, Wald H, Franitza S, Weiss I, Avniel S, Boaz P, Hanna J, Zamir G, Eid A, Mandelboim O, Spengler U, Galun E, Peled A. 2004. Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur J Immunol 34(4):1164-1174.
209. Wald O, Weiss ID, Galun E, Peled A. 2007. Chemokines in hepatitis C virus infection: pathogenesis, prognosis and therapeutics. Cytokine 39:50-62.
210. Wang X, Yue TL, Ohlstein EH, Sung CP, Feuerstein GZ. 1996. Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and infammatory response. J Biol Chem 271:24.
211. Ward SH, Westwick J. 1998. Chemokines: understanding their role in T-lymphocyte biology. Biochem. J. 333; 457-470
212. Webb LM, Ehrengruber MU, Clark-Lewis I, Baggiolini M, Rot A. 1993. Binding to eparan sulfate or heparin enhances neutrophil responses to interleukin gmas and enigmas. Nat Rev Immunol 4:360-370.
213. Weber KS, von Hundelshausen P, Clark Lewis I, Weber PC, Weber C. 1999. Diferential immobilization and hierarchical involvement of chemokines in monocyte arrest and transmigration on infamed endothelium in shear fow. Eur J Immunol 29:700-712.
214. Williams EJ, Haque S, Banks C, Johnson P, Sarsefeld N. 2000. Distribution of the interleukin-8 receptors, CXCR1 and CXCR2, in infamed gut tissue. J Pathol 192: 533.
215. Wolpe SD, Cerani A. 1989. Macrophage infammatory proteins 1 and 2: members of a novel superfamily of cytokines. FASEB J 3: 2565-2573.
216. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Rufng N, Borsetti A, Cardoso AA, Desjardin E, Newman W, Gerard C, Sodroski J. 1996. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384:179-183.
217. Yamauchi F, Kashem A, Endoh M, Nomoto Y, Sakai H. 1996. Detection of monocyte chemoattractant protein-1 (MCP-1) and its receptors in mesangial proliferative glomerulonephritis. Nephrology 2:93-99.
218. Yang G, Volk A, Petley T, Emmell E, Giles-Komar J, Shang X, Li J, Das AM, Shealy D, Griswold DE, Li L. 2004. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, infammation and airway remodeling. Cytokine 28:224-232.
219. Yang S, Eckmann L, Panja A, Kagnof M. 1997. Diferential and regulated expression of C-X-C, C-C and C-chemokines by human colon epithelial cells. Gastroenterology 113:1214-1223.
220. Yasumoto K, Okamoto S, Mukaida N, Murakami S, Mai M, Matsushima K. 1992. Tumor necrosis factor alpha and interferon gamma synergistically induce interleukin 8 production in a human gastric cancer cell line through acting concurrently on AP-1 and NF-KB-like binding sites of the interleukin 8 gene. J Biol Chem 267:22506-22511.
221. Ying S, Taborda L, Meng Q, Humbert M, Kay AB. 1995. Te kinetics of allergen induced transcription of messenger RNA for monocyte chemotactic protein-3 and RANTES in the skin of human atopic subjects: relationship to eosinophil, T cell, and macrophage recruitment. J Exp Med 181:2153-2159.
222. Yokoyama H, Wada T, Furuichi K, Segawa C, Shimizu M, Kobayashi K, Su S, Mukaida N, Matsushima K. 1998. Urinary levels of chemokines (MCAF/ MCP-1, IL-8) refect distinct disease activities and phases of human IgA nephropathy. J Leukocyte Biol 63:493-499.
223. Zaballos A, Gutierrez J, Varona R, Ardavin C, Marquez G. 1999. Cutting edge: identifcation of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. J Immunol 162:671-675.
224. Zhao DX, Hu Y, Miller GG, Luster AD, Mitchell RN, Libby P. 2002. Diferential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN inducible protein 10, monokine induced by IFN, and IFN-inducible Tcell alpha chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. J Immunol 169:1556-1560.
225. Zheng B, Ozen Z, Zhang X, De Silva S, Marinova E, Guo L, Wansley D, Huston DP, West MR, Han S. 2005. CXCL13 neutralization reduces the severity of collagen-induced arthritis. Arthritis Rheum 52:620-626.
226. Zhou Y, Kurihara T, Ryseck RP, Yang Y, Ryan C, Loy J, Warr G, Bravo R. 1998. Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J Immunol 160: 4018-4025.
227. Zlotnik A. 2006. Chemokines and cancer. Int J Cancer 119:2026-2029.
228. Zlotnik A, Yoshie O. 2000. Chemokines: a new classifcation system and their role in immunity. Immunity 12:21-26.
229. Zlotnik A, Morales J, Hedrick JA. 1999. Recent advances in chemokines and chemokine receptors. Crit Rev Immunol 19:1-47. (Pubitemid 29062100)
230. Zlotnik A, Yoshie O, Nomiyama H. 2006. Te chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 7:1-11.